343 related articles for article (PubMed ID: 19952993)
1. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch.
Yamashiro K; Tsujikawa A; Miyamoto K; Oh H; Otani A; Tamuara H; Ooto S; Sasahara M; Iwama D; Yoshimura N
Retina; 2010 Mar; 30(3):485-90. PubMed ID: 19952993
[TBL] [Abstract][Full Text] [Related]
2. Severe intraocular inflammation after intravitreal injection of bevacizumab.
Sato T; Emi K; Ikeda T; Bando H; Sato S; Morita S; Oyagi T; Sawada K
Ophthalmology; 2010 Mar; 117(3):512-6, 516.e1-2. PubMed ID: 20031229
[TBL] [Abstract][Full Text] [Related]
3. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration.
Wickremasinghe SS; Michalova K; Gilhotra J; Guymer RH; Harper CA; Wong TY; Qureshi S
Ophthalmology; 2008 Nov; 115(11):1911-5. PubMed ID: 18672291
[TBL] [Abstract][Full Text] [Related]
4. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
6. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
7. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections.
Cheung CS; Wong AW; Lui A; Kertes PJ; Devenyi RG; Lam WC
Ophthalmology; 2012 Aug; 119(8):1609-14. PubMed ID: 22480743
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor.
Mezad-Koursh D; Goldstein M; Heilwail G; Zayit-Soudry S; Loewenstein A; Barak A
Retina; 2010; 30(7):1051-7. PubMed ID: 20616683
[TBL] [Abstract][Full Text] [Related]
9. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
Retina; 2007; 27(4):439-44. PubMed ID: 17420695
[TBL] [Abstract][Full Text] [Related]
12. Bilateral simultaneous intravitreal injections in the office setting.
Bakri SJ; Risco M; Edwards AO; Pulido JS
Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
[TBL] [Abstract][Full Text] [Related]
14. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection.
Mason JO; White MF; Feist RM; Thomley ML; Albert MA; Persaud TO; Yunker JJ; Vail RS
Retina; 2008 Apr; 28(4):564-7. PubMed ID: 18398358
[TBL] [Abstract][Full Text] [Related]
15. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
16. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
Chan CK; Meyer CH; Gross JG; Abraham P; Nuthi AS; Kokame GT; Lin SG; Rauser ME; Kaiser PK
Retina; 2007 Jun; 27(5):541-51. PubMed ID: 17558314
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
18. Vitreous web after pars plana vitrectomy and bevacizumab with fluid-air exchange.
Chiang A; Reddy S; Tsui I; Hubschman JP
Semin Ophthalmol; 2011 Jan; 26(1):25-7. PubMed ID: 21275601
[TBL] [Abstract][Full Text] [Related]
19. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
[TBL] [Abstract][Full Text] [Related]
20. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.
Ronan SM; Yoganathan P; Chien FY; Corcóstegui IA; Blumenkranz MS; Deramo VA; Elner SG; Fastenberg DA; Johnson MW; López M; Mateo C; Moshfeghi DM; Navarro R; Rosenblatt BJ; Sanislo SR; Saxe SJ; Zacks DN
Retina; 2007 Jun; 27(5):535-40. PubMed ID: 17558313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
